LFCR — Lifecore Biomedical Income Statement
0.000.00%
Last trade - 00:00
- $148.15m
- $234.04m
- $103.27m
- 23
- 35
- 38
- 23
2019 May 26th | R2020 May 31st | R2021 May 30th | R2022 May 29th | 2023 May 28th | |
---|---|---|---|---|---|
Period Length: | 52 W | 53 W | 52 W | 52 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 558 | 160 | 101 | 111 | 103 |
Cost of Revenue | |||||
Gross Profit | 81 | 39.4 | 38.9 | 39.1 | 28 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 552 | 186 | 111 | 123 | 149 |
Operating Profit | 5.47 | -25.9 | -9.93 | -11.8 | -45.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3.64 | -30.6 | -29.8 | -20.7 | -63.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.12 | -21.9 | -23.4 | -15.5 | -64.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 0.411 | -38.2 | -32.3 | -117 | -99.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.411 | -38.2 | -32.3 | -117 | -99.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.182 | -0.371 | 0.179 | 1.73 | -1.13 |